Poliomyelitis is a vaccine-preventable viral infection caused by poliovirus types 1, 2, and 3, transmitted primarily through fecal-oral routes and capable of causing irreversible paralysis in roughly 1 of every 200 unvaccinated wild poliovirus type 1 infections per WHO. Wild poliovirus type 2 was certified eradicated in 2015 and wild type 3 in 2019, leaving only wild poliovirus type 1 (WPV1) circulating in Afghanistan and Pakistan. Yet 2024 saw poliovirus detected in wastewater across multiple cities (London, New York, Berlin, Helsinki, Gaza), polio-related travel advisories from CDC for 30+ countries, and the highest cVDPV2 case count in years.

The reason 50-year-old eradication targets keep slipping is a combination of vaccination gaps, vaccine-derived poliovirus that emerges from oral vaccine in undervaccinated populations, and the pandemic-era collapse in routine immunization. Polio is a useful case study in why "we're done with that one" is rarely true for any pathogen humans haven't actively driven out, and why surveillance keeps mattering long after the last domestic case. Polio readiness sits inside the broader pandemic preparedness framework alongside surveillance, vaccination, and outbreak response capacity.

Key Takeaways

What is polio and why isn't it eradicated yet?

Polio is a viral infection caused by poliovirus, transmitted mostly through fecal-oral routes (sometimes via respiratory droplets), with most infections asymptomatic but roughly 1 in 200 leading to flaccid paralysis. WHO's Global Polio Eradication Initiative has reduced wild polio cases by over 99.9% since 1988, but elimination has not crossed the finish line because two specific transmission reservoirs (Afghanistan, Pakistan) and vaccine-derived virus emergence continue to seed outbreaks.

The eradication math is harder than it looks because most polio infections are silent. For every paralytic case, hundreds of asymptomatic infected people are shedding virus. Detecting a single paralytic case in a region means transmission has already been quietly going for weeks to months. That's why wastewater surveillance, which catches viral shedding before any case appears, has become the primary tool in countries with high vaccination coverage.

Conflict and humanitarian access also matter. Polio reservoirs in Pakistan and Afghanistan persist partly because immunization campaigns have been disrupted by violence against vaccinators and political instability. WHO's Global Eradication Initiative has missed multiple targeted eradication dates for these reasons. Our disease eradication prospects post covers what makes polio different from smallpox, the only human disease successfully eradicated to date.

What is vaccine-derived poliovirus and why does it matter?

Vaccine-derived poliovirus (VDPV) is poliovirus that originated from the live attenuated oral polio vaccine (OPV), then mutated back toward neurovirulence after circulating in undervaccinated populations for several months to a year. WHO reports that circulating VDPV type 2 (cVDPV2) caused most polio cases globally between 2018 and 2024, emerging in regions where vaccination coverage dropped below the threshold needed to prevent person-to-person transmission of the vaccine virus.

The mechanism is intuitive once you see it. OPV uses live, weakened poliovirus that replicates briefly in the gut and confers immunity. Vaccinated people shed the weakened virus in stool for weeks. In communities with high coverage, the shed virus contacts mostly immune people and dies out. In communities with low coverage, it passes through unvaccinated people repeatedly, accumulating mutations, until it regains the ability to cause paralysis.

WHO's response since 2016 has been a transition away from trivalent OPV (which contained type 2) to bivalent OPV (types 1 and 3 only) and the new nOPV2 (a genetically stabilized type 2 vaccine designed to resist reversion). The nOPV2 rollout has been the largest emergency-use vaccine deployment in WHO history. Vaccination coverage in OPV-using countries is the only durable solution.

How does wastewater surveillance detect polio circulation?

Wastewater surveillance tests sewage samples by RT-PCR for poliovirus genome fragments shed in stool by infected people, asymptomatic or paralytic. CDC, the UK Health Security Agency, and Israel's Ministry of Health all run weekly wastewater testing in selected catchment areas. A single positive sample triggers expanded sampling, sequencing to identify wild vs vaccine-derived virus, and targeted vaccination response in the catchment population.

Wastewater detected polio in London (2022, multiple districts), New York and surrounding counties (2022-2023), Jerusalem (2022, 2025), Berlin and Helsinki (2024), and Gaza (2024-2025) without any associated paralytic cases in most of those locations. The New York exception (one paralytic case in an unvaccinated adult in Rockland County, July 2022) was the first US paralytic polio case since 2013 and confirmed sustained local transmission.

Sequencing distinguishes wild polio from vaccine-derived strains and identifies the geographic origin. Most US and European detections traced to vaccine-derived strains imported from regions still using OPV. The wastewater surveillance outbreaks post covers how the same technique works for other pathogens including SARS-CoV-2, mpox, and antibiotic-resistant organisms.

Should adults get a polio booster?

Most US adults who completed the routine childhood polio series (4 IPV doses by age 6) are considered protected for life and do not need boosters. CDC recommends a single adult IPV booster only for: travelers to countries with WPV1 or cVDPV transmission, healthcare workers handling specimens that could contain poliovirus, and outbreak responders or laboratory workers with potential exposure.

The traveler indication has expanded. CDC's traveler health pages currently recommend a one-time adult IPV booster for travel to Afghanistan, Pakistan, parts of Africa with active cVDPV transmission, and recently for some Middle East destinations following Gaza-region detections. Check current recommendations before any international travel, especially humanitarian or extended deployments. Our travel vaccinations timing guide covers polio alongside other pre-departure vaccines.

For US adults who never received any polio vaccine (rare but not zero, especially among adults from countries with poor vaccine coverage), CDC recommends 3 IPV doses on a 0, 1-2 month, 6-12 month schedule. Adults with incomplete childhood series should complete the full schedule. Vaccination history is acceptable based on documentation or sometimes serological testing.

How would a polio resurgence be contained?

A localized polio resurgence triggers a layered response: case investigation, contact tracing, expanded wastewater surveillance to define the affected area, and aggressive immunization of unvaccinated and undervaccinated people in the catchment population. WHO and CDC maintain emergency vaccine stockpiles, and outbreak response can deploy targeted vaccination within days of confirmation.

The 2022 New York response is the most recent US example. After the Rockland County paralytic case and concurrent wastewater detections, state and local health departments ran targeted IPV campaigns in undervaccinated communities, expanded routine immunization outreach, and conducted serosurveys to identify pockets of low immunity. Wastewater surveillance continued for over a year to confirm transmission had stopped.

International response uses oral polio vaccine (typically nOPV2 for type 2 outbreaks) for rapid administration and superior gut immunity. WHO's Global Polio Eradication Initiative coordinates supplemental immunization activities (SIAs) across borders when transmission threatens to spread. The window from first wastewater signal to controlled transmission is usually 6 to 18 months when vaccination response is deployed quickly.

FAQ

Is the polio vaccine safe?

Yes. Inactivated polio vaccine (IPV), used in the US since 2000, contains killed virus and cannot cause polio. Adverse events are typically mild (injection site soreness, low fever). Oral polio vaccine (OPV), used internationally, has rare risk of vaccine-associated paralytic polio (roughly 1 in 2.7 million doses) and rare circulating vaccine-derived polio in undervaccinated populations, but provides better gut immunity for outbreak control.

Why did the US stop using oral polio vaccine?

In 2000, CDC switched the routine US schedule from oral polio vaccine (OPV) to inactivated polio vaccine (IPV) because the only paralytic polio cases occurring in the US were vaccine-associated paralytic polio from OPV, since wild polio had been eliminated domestically. IPV provides excellent individual protection without the live-virus risk. Most high-income countries with eliminated wild polio have made the same switch.

How long does polio vaccine immunity last?

A complete IPV series in childhood provides immunity considered to last for life in healthy adults. Antibody levels from IPV may decline over decades, but immune memory persists and the vaccine has been highly effective in preventing paralytic disease. The single adult booster recommended for at-risk travelers is precautionary, raising antibody levels rapidly for the duration of exposure.

Can polio be eradicated?

Eradication is technically possible because polio has no animal reservoir and an effective vaccine exists, the same conditions that allowed smallpox eradication. WHO's Global Polio Eradication Initiative has set and missed multiple eradication dates due to access, vaccination coverage, and vaccine-derived virus issues. The two main remaining barriers are vaccine refusal and conflict-affected access in Afghanistan and Pakistan.

What does polio paralysis look like?

Most polio infections cause no symptoms or mild flu-like illness. In about 1 in 200 cases, the virus enters the central nervous system and destroys motor neurons, causing acute flaccid paralysis (sudden weakness, often asymmetric, usually in the legs). Some patients recover partial function over months. A subset develop post-polio syndrome decades later, with progressive muscle weakness in previously affected limbs.